Larimar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Files Prospectus for Public Offering, Raising Approximately $64.4 Million
Larimar Therapeutics Inc. has filed a prospectus supplement with the Securities and Exchange Commission as part of its public offering of common stock. The company plans to issue and sell 18,750,000 shares at a price of $3.20 per share, with an option for underwriters to purchase an additional 2,812,500 shares. The total net proceeds from the offering, after expenses, are expected to be approximately $64.4 million. The offering is being managed by Leerink Partners LLC, Guggenheim Securities, LLC, Truist Securities, Inc., and William Blair & Company, L.L.C., and is set to close pending customary conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-169818), on July 31, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。